ALK-Abello shares shine on Q2 sales, investment details

Alk-Abello A/S

21/08/2025 08:56

** Shares in ALK-Abello ALKb.CO rise 4% after the Danish allergy solutions maker reported more details on Q2 sales

 ** On August 12, the company announced preliminary Q2 EBIT of 375 million Danish crowns ($58 million), exceeding the consensus forecast of 359 million crowns

** Jefferies says revenue details show Q2 tablet sales were 2% ahead of market forecasts prior to the pre-announcement, with Other Products 14% above estimates

** Whilst tablet stocking in Europe fell from Q1, volume growth was maintained driven by strong Acarizax uptake, the broker adds

** The company also says it will allocate additional funds to strategic growth investments in H2 to support the launches of neffy and paediatric tablets

** This should aid continued growth momentum into the medium term, Jefferies says

** The ALK-Abello stock is among top performers on Europe's benchmark STOXX 600 index .STOXX

($1 = 6.4164 Danish crowns)

(Reporting by Agnieszka Gosciak-Rabalska)

((Agnieszka.gosciak@thomsonreuters.com))